TLPH · XBRL financial data

Talphera financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (TLPH's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	1,178	1,769*	1,433	1,909	2,053	1,323*	1,169	1,500	1,803	1,561*	1,650	1,690
Selling, general and administrative	2,248	2,795*	2,804	2,361	1,696	1,673*	1,774	2,193	1,620	1,892*	2,298	2,234
Operating income (loss)	—	year only	—	(4,270)	(3,749)	(2,996)*	(2,916)	(3,693)	(3,422)	(3,453)*	(3,948)	(3,924)
Interest expense	0	0*	0	0	0	0*	—	—	—	—	—	—
Income tax expense (benefit)	2	(5)*	—	0	0	0*	—	—	—	year only	—	—
Net income (loss)	(1,357)	(4,517)*	(3,954)	(3,827)	(3,353)	(1,870)*	(2,593)	(3,489)	(4,436)	(3,772)*	(2,556)	(4,312)
Earnings per share, basic USD per share	(0.08)	—	(0.16)	(0.15)	(0.13)	(0.07)*	(0.10)	(0.10)	(0.11)	—	(0.04)	(0.06)
Earnings per share, diluted USD per share	(0.08)	—	(0.16)	—	—	—	(0.10)	—	—	—	—	—
Weighted average shares, basic thousands of shares	16,758	—	24,722	26,202	26,213	26,238*	26,268	34,530	41,453	—	69,822	75,527
Weighted average shares, diluted thousands of shares	16,758	—	—	—	—	—	—	—	—	—	—	—

Fiscal quarters (TLPH's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	13,389	5,721	12,122	13,423	11,117	8,863	5,388	6,791	3,457	5,894	3,823	742
Short-term investments	0	3,660	6,462	600	0	0	—	—	17,832	14,487	17,285	16,334
Prepaid and other current assets	1,017	2,175	1,369	2,014	1,078	554	788	905	634	519	228	911
Total current assets	14,422	11,556	19,953	16,037	12,195	9,417	6,176	7,696	21,923	20,900	21,336	17,987
Total assets	23,261	20,395	28,772	24,856	21,014	18,236	14,995	16,515	30,742	29,719	30,155	26,806
Accounts payable	1,026	1,336	1,274	808	396	670	326	835	526	544	927	387
Accrued liabilities	1,792	2,445	1,340	1,743	1,643	1,254	1,013	1,145	2,036	2,615	2,448	3,151
Current portion of long-term debt	0	0	—	—	—	—	—	—	—	—	—	—
Total current liabilities	3,574	4,512	3,344	3,274	2,762	2,647	1,989	2,630	3,212	3,809	4,025	4,188
Total liabilities	4,954	6,290	12,438	12,126	11,373	10,235	9,396	9,888	11,565	12,684	11,677	12,400
Accumulated deficit	(439,709)	(444,226)	(448,180)	(452,007)	(455,360)	(457,230)	(459,823)	(463,312)	(467,748)	(471,520)	(474,076)	(478,388)
Total stockholders' equity	18,307	14,105	16,334	12,730	9,641	8,001	5,599	6,627	19,177	17,035	18,478	14,406
Total liabilities and equity	23,261	20,395	28,772	24,856	21,014	18,236	14,995	16,515	30,742	29,719	30,155	26,806
Common shares outstanding (cover page) thousands of shares	16,952	16,969	16,993	16,993	17,029	17,098	20,503	20,523	46,610	50,050	51,900	51,906

Fiscal quarters (TLPH's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(1,357)	(4,517)*	(3,954)	(3,827)	(3,353)	(1,870)*	(2,593)	(3,489)	(4,436)	(3,772)*	(2,556)	(4,312)
Stock-based compensation	378*	311*	302	223*	234*	230*	196	166*	152*	185*	214	243*
Depreciation and amortization	0*	0*	0	0*	0*	0*	—	—	—	—	—	—
Net cash from operating activities	(2,960)*	(3,949)*	(2,883)	(4,610)*	(2,936)*	(2,254)*	(3,470)	(2,948)*	(2,510)*	(2,436)*	(3,400)	(3,924)*
Purchases of property and equipment	0*	0*	0	0*	0*	0*	—	—	—	—	—	—
Net cash from investing activities	0*	(3,651)*	(2,730)	5,911*	600*	0*	0	0*	(17,815)*	3,470*	(2,714)	1,104*
Repayments of long-term debt	0*	0*	0	0*	0*	0*	—	—	—	—	—	—
Net cash from financing activities	8,939*	(68)*	12,014	0*	30*	0*	(5)	4,351*	16,991*	1,403*	4,043	(261)*
Net change in cash	5,979*	(7,668)*	6,401	1,301*	(2,306)*	(2,254)*	(3,475)	1,403*	(3,334)*	2,437*	(2,071)	(3,081)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Talphera	742	not reported	(3,924)*	51.9M	4.4 quarters	Q2 FY26 10-QJun 30, 2026
Biovie	8,977	not reported	(4,122)*	7.5M	2.2 quarters	Q4 FY26 10-KJun 30, 2026
Processa Pharmaceuticals	196	not reported	(1,996)*	2.8M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
GT Biopharma	4,960	not reported	(4,260)*	45.1M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Orgenesis	78	301*	(2,098)*	9.8M	0.0 quarters	Q4 FY24 10-KDec 31, 2024
TherapeuticsMD	9,189	not reported	not reported	11.6M	—	Q2 FY26 10-QJun 30, 2026
Oncotelic Therapeutics	186	250	(92)*	457.5M	2.0 quarters	Q2 FY26 10-QJun 30, 2026
VivoSim Labs	1,670	18	(3,213)	14.9M	0.5 quarters	Q1 FY27 10-QJun 30, 2026
Genprex	15,154	not reported	(5,139)*	819,709	2.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.